Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 2/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.74 |
| ▸ | MEN1 | O00255 | 2/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.69 |
| ▸ | TSHR | P16473 | 2/20 | 0.69 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.67 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.64 |
| ▸ | HTT | P42858 | 2/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.62 |
| ▸ | MAPT | P10636 | 1/20 | 0.62 |
| ▸ | HPGD | P15428 | 1/20 | 0.62 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.60 |
| ▸ | POLB | P06746 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29510859 | 1.00 | NOTUM (1.00) | NOTUMSMN1; SMN2MEN1KMT2ATSHR | |
| SCHEMBL5423105 | 0.95 | NOTUM (0.90) | NOTUMSMN1; SMN2MEN1KMT2ATSHR | |
| SCHEMBL396037 | 0.89 | NOTUM (1.00) | NOTUMSMN1; SMN2MEN1KMT2ATSHR | |
| SCHEMBL29449723 | 0.89 | NOTUM (1.00) | NOTUMSMN1; SMN2MEN1KMT2ATSHR | |
| SCHEMBL4019697 | 0.85 | SMN1; SMN2 (0.79) | NOTUMSMN1; SMN2MEN1KMT2ATSHR | |
| SCHEMBL29353444 | 0.84 | SMN1; SMN2 (0.77) | NOTUMSMN1; SMN2MEN1KMT2ATSHR | |
| SCHEMBL4291340 | 0.84 | SMN1; SMN2 (0.77) | NOTUMSMN1; SMN2MEN1KMT2ATSHR | |
| SCHEMBL2829456 | 0.84 | SMN1; SMN2 (0.77) | NOTUMSMN1; SMN2MEN1KMT2ATSHR | |
| SCHEMBL28250157 | 0.83 | SMN1; SMN2 (0.76) | NOTUMSMN1; SMN2MEN1KMT2ATSHR | |
| SCHEMBL30956358 | 0.83 | SMN1; SMN2 (0.76) | NOTUMSMN1; SMN2MEN1KMT2ATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 398 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230416786-A1 | USE OF AMINOQUINOLINE COMPOUNDS FOR HIGHER GENE INTEGRATION | CELLECTIS SA (FR) | 2023-12-28 | — | — | US | claimed |
| EP-4251746-A1 | USE OF AMINOQUINOLINE COMPOUNDS FOR HIGHER GENE INTEGRATION | Cellectis SA (FR) | 2023-10-04 | — | — | EP | claimed |
| US-20230000893-A1 | Antiviral Agents and Nucleoside Analogs for Treatment of Zika Virus | UNIV EMORY (US) | 2023-01-05 | — | — | US | claimed |
| CN-114853642-A | Synthesis method for directly alkylating benzyl position of aromatic compound | 西湖大学 | 2022-08-05 | — | — | CN | claimed |
| WO-2022112596-A1 | USE OF AMINOQUINOLINE COMPOUNDS FOR HIGHER GENE INTEGRATION | CELLECTIS SA (FR) | 2022-06-02 | — | — | WO | claimed |
| EP-3174932-B1 | CURE ACCELERATORS FOR ANAEROBIC CURABLE COMPOSITIONS | Henkel IP & Holding GmbH (DE) | 2021-06-09 | — | — | EP | claimed |
| US-9969863-B2 | Cure accelerators for anaerobic curable compositions | Henkel IP & Holding GmbH (DE) | 2018-05-15 | — | — | US | claimed |
| WO-2017165489-A1 | ANTIVIRAL AGENTS FOR TREATING ZIKA AND DENGUE VIRUS INFECTIONS | EMORY UNIVERSITY (US) | 2017-09-28 | — | — | WO | claimed |
| US-20170137606-A1 | CURE ACCELERATORS FOR ANAEROBIC CURABLE COMPOSITIONS | HENKEL AG & CO. KGAA (DE) | 2017-05-18 | — | — | US | claimed |
| EP-2694086-A1 | MHC ENGAGEMENT AND CLIP MODULATION FOR THE TREATMENT OF DISEASE | The Texas A&M University System (US) | 2014-02-12 | — | — | EP | claimed |
| EP-1581167-A4 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PARKINSON'S DISEASE AND TARDIVE DYSKINESIAS | ALPHA RES GROUP LLC (US) | 2008-10-29 | — | — | EP | claimed |
| JP-2006514917-A | — | — | 2006-05-18 | — | — | JP | claimed |
| EP-1581167-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PARKINSON'S DISEASE AND TARDIVE DYSKINESIAS | Alpha Research Group, LLC (US) | 2005-10-05 | — | — | EP | claimed |
| EP-1261340-A4 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PARKINSON'S DISEASE | ALPHA RES GROUP LLC (US) | 2005-05-04 | — | — | EP | claimed |
| US-20040229908-A1 | Compositions and methods for the treatment of Parkinson's disease and tardive dyskinesias | Greenlee, Winner and Sullivan, P.C. | 2004-11-18 | — | — | US | claimed |
| WO-2004004660-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PARKINSON’S DISEASE AND TARDIVE DYSKINESIAS | ALPHA RESEARCH GROUP, L.L.C. (US) | 2004-01-15 | — | — | WO | claimed |
| JP-2004500331-A | — | — | 2004-01-08 | — | — | JP | claimed |
| US-20020198231-A1 | Compositions and methods for the treatment of Parkinson's disease | Greenlee, Winner and Sullivan, P.C. | 2002-12-26 | — | — | US | claimed |
| EP-1261340-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PARKINSON'S DISEASE | Alpha Research Group, LLC (US) | 2002-12-04 | — | — | EP | claimed |
| WO-2001003649-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PARKINSON'S DISEASE | ALPHA RESEARCH GROUP, LLC (US) | 2001-01-18 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170137606-A1 | CURE ACCELERATORS FOR ANAEROBIC CURABLE COMPOSITIONS | AHCY, AHCYL1, MGMT | NOTUM 2204/4885SMN1; SMN2 1101/4885MEN1 3328/4885 |
| US-20230000893-A1 | Antiviral Agents and Nucleoside Analogs for Treatment of Zika Virus | SAMHD1, PNP, NUDT1 | NOTUM 3816/4885SMN1; SMN2 986/4885MEN1 3818/4885 |
| US-20230416786-A1 | USE OF AMINOQUINOLINE COMPOUNDS FOR HIGHER GENE INTEGRATION | ERCC4, LIG4, LIG3 | NOTUM 1359/4885SMN1; SMN2 4286/4885MEN1 4031/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.